Your Messages Inbox
Your Article Summary
See Latest ArticlesResults from Abbotts PROSPECT Study Provide New Insight into Role of Vulnerable Plaque in Coronary Artery Disease
Abbott, 09/25/09
Abbott announced primary results from its groundbreaking PROSPECT clinical trial. PROSPECT is the first prospective natural history study to evaluate the role of vulnerable plaque in unexpected heart attacks and the natural progression of coronary artery disease. Results were presented during the late–breaking clinical trials session by Gregg W. Stone, M.D., professor of medicine at Columbia University Medical Center, during the 2009 Transcatheter Cardiovascular Therapeutics annual meeting.
Today in Conferences/Meetings...keeping you current
Receive free subspecialty "5-minute updates" via email
Quality of trials reported as conference abstracts in China: How well are they reported
International Journal of Technology Assessment in Health Care, 11/05/09
User Groups Prove Helpful
HealthDataManagement, 11/03/09
Salix Pharmaceuticals Reviews American Association For The Study Of Liver Diseases Annual Meeting
Salix Pharmaceuticals, 11/03/09
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
Article Search
Sponsor